| Biotechnology Industry | Healthcare Sector | Mr. Peter John Harrison MA CEO | XFRA Exchange | GB00B4QVDF07 ISIN |
| United Kingdom Country | 17 Employees | - Last Dividend | - Last Split | - IPO Date |
Bioventix PLC is a biotechnology company specialized in the creation, manufacture, and supply of sheep monoclonal antibodies (SMAs) for use in diagnostic applications across the globe. Its portfolio serves a variety of medical and industrial testing needs, including thyroid function, vitamin D levels, cardiac markers, and more. Established in 2003, Bioventix is based in Farnham, the United Kingdom, positioning itself as a critical partner in the diagnostic and healthcare industry by providing high-quality, precise antibodies crucial for the development of various diagnostic tests.
These antibodies are used in the diagnosis and monitoring of thyroid disorders, vitamin D deficiency, cardiac issues, fertility problems, drugs of abuse, and various oncology indications. Bioventix’s portfolio of purified sheep monoclonal antibodies showcases the company's capacity for innovation and its role in enhancing diagnostic accuracy and patient care.
This product is designed to monitor human exposure to industrial pollutants, representing Bioventix’s commitment to public health and safety. The kit uses enzyme-linked immunosorbent assay technology to detect hydroxypyrene, a metabolite of polycyclic aromatic hydrocarbons, which are major pollutants.
Bioventix offers custom antibody production services, providing clients with tailored solutions for their diagnostic and research needs. This service underscores the company’s flexibility and expertise in creating high-quality, specific antibodies to meet the diverse requirements of the diagnostic and biotechnology sectors.